Overture Life, a Palo Alto, CA-based firm which focuses on embryology lab procedures, raised $20.6M.
Bakers included Overwater Ventures, GV, and Khosla Ventures.
The corporate intends to make use of the funds to broaden fertility entry by making IVF labs extra reproducible, environment friendly, and fewer cost-intensive.
Led by CEO Hans Gangeskar, Overture Life integrates engineering, reproductive drugs, and regulatory-grade validation to modernize embryology lab procedures, significantly egg freezing and embryo dealing with, in ways in which decrease repeated cycles, improve throughput, and cut back the general price of IVF. With R&D in Spain and lively U.S. operations, together with a CLIA-licensed laboratory for non-invasive embryo choice, Overture unites robotics, analytics, and medical rigor to ship instruments that clinics and sufferers can use. Its DaVitri platform improves reliability and consistency in IVF, giving girls and households worldwide extra management over their fertility timelines.
The corporate can also be asserting its newly achieved CLIA (medical laboratory enchancment amendments) license in the US to fulfill federal medical laboratory requirements for m|z, its AI-powered, non-invasive metabolomic check for embryo choice.
The spherical introduced the whole quantity to $57M.
FinSMEs
25/04/2025
